Imagine treating a bladder tumor like a quick dental filling instead of a major hospital surgery. This tool combines four steps—numbing, cutting, removing, and cauterizing—into one single device. It allows patients to stay awake and go home immediately, skipping the operating room and general anesthesia.
Bladder cancer treatment relies on 1960s technology requiring expensive operating rooms and general anesthesia. This creates high costs, long waiting times, and a 75% recurrence rate.
A 4-in-1 surgical instrument that integrates local anesthesia delivery, tissue excision, specimen transport, and coagulation into one tool.
If you are a manufacturer dealing with stagnant urology product lines—this project developed a 4-in-1 surgical instrument that enables 20-minute outpatient procedures. It replaces outdated 1960s-era tools with a deep-tech integrated design.
If you are a clinic owner dealing with long waiting lists and expensive OR rentals—this project developed a tool that shifts interventions from operating theatres to the office. This reduces dependence on scarce theatre capacity and anesthesia.
If you are an insurer dealing with the fact that 60% of bladder cancer costs come from surveillance and recurrences—this project developed a precision tool for more effective tumor removal. This could lower the long-term financial burden of cancer management.
Bladder cancer is currently one of the most expensive to manage, with 60% of costs linked to surveillance and recurrences. By moving surgery to an outpatient setting, the tool reduces expensive operating room and anesthesia costs.
The project objectives specifically include the industrialization of the device and the transfer to production to prepare for market introduction.
Based on available project data, the technology is developed by Multi4 Medical AB using deep tech innovations in instrument engineering design, though specific patent numbers are not listed.
The project is working toward certification according to the Medical Device Regulation (MDR) to achieve CE marking.
The project runs from 2024-09-01 to 2026-08-31, with first-in-human feasibility studies already conducted on 17 patients.
The project is led by a single Swedish SME, Multi4 Medical AB, with a 100% industry ratio. This lean structure suggests a fast-track commercial focus, as there are no university or research partners slowing down the transition from clinical trial to market.
Contact Miden Melle-Hannah at Multi4 Medical AB
Contact us to explore licensing opportunities for this urology innovation.
